ArticleMarine biotechnology (New York, N.Y.)2026
Integrated DIA-PRM proteomics Deciphers the molecular mechanisms and identifies core biomarkers of relative resistance to decapod iridescent Virus 1 (DIV1) in Macrobrachium rosenbergii.
Article in Marine biotechnology (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Macrobrachium rosenbergii is a pillar species in global freshwater crustacean aquaculture. Decapod iridescent virus 1 (DIV1) causes 60%-90% cumulative mortality in cultured ponds, leading to massive economic losses with no effective control measures. This study aimed to elucidate DIV1 relative resistance mechanisms and screen core biomarkers in M. rosenbergii. We constructed artificially selected DIV1-resistant (GK), susceptible (YG) and control (DZ) group from M. rosenbergii populations. After standardized DIV1 challenge, plasma samples were collected at 72 h post-infection, and analyzed via integrated DIA-MS proteomics, PRM targeted validation and bioinformatics analysis. GK group had a 2.7-fold longer median survival time (118 h vs. 44 h in YG) and 69% lower cumulative mortality risk. The core relative resistance mechanism was identified as enhanced proteostasis network plus selective metabolic reprogramming. PRM validation of 12 core DEPs showed high consistency with DIA. results (Pearson r = 0.92, P < 0.001), with 5 key proteins forming a multi-dimensional antiviral network. This study first reveals a non-canonical anti-DIV1 immune paradigm in crustaceans. The screened core biomarkers provide key molecular targets for M. rosenbergii precision breeding and field early warning, laying a theoretical foundation for sustainable DIV1 control.
Indexed as
Identifiers
42550270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.